Compare Biocon Ltd with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PANACEA BIOTECH - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PANACEA BIOTECH BIOCON /
PANACEA BIOTECH
 
P/E (TTM) x 17.4 12.6 138.1% View Chart
P/BV x 2.7 3.0 88.9% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 BIOCON    PANACEA BIOTECH
EQUITY SHARE DATA
    BIOCON
Mar-18
PANACEA BIOTECH
Mar-18
BIOCON /
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,188364 326.4%   
Low Rs305129 236.3%   
Sales per share (Unadj.) Rs68.796.8 71.0%  
Earnings per share (Unadj.) Rs7.6-12.4 -60.9%  
Cash flow per share (Unadj.) Rs14.0-2.9 -489.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.350.4 171.3%  
Shares outstanding (eoy) m600.0061.25 979.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.5 426.4%   
Avg P/E ratio x98.9-19.9 -497.5%  
P/CF ratio (eoy) x53.4-86.4 -61.8%  
Price / Book Value ratio x8.64.9 176.7%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,90015,101 2,966.0%   
No. of employees `0006.12.5 249.1%   
Total wages/salary Rs m9,3111,516 614.2%   
Avg. sales/employee Rs Th6,705.82,401.9 279.2%   
Avg. wages/employee Rs Th1,514.2614.2 246.5%   
Avg. net profit/employee Rs Th736.9-307.9 -239.3%   
INCOME DATA
Net Sales Rs m41,2345,928 695.6%  
Other income Rs m2,06282 2,505.5%   
Total revenues Rs m43,2966,010 720.4%   
Gross profit Rs m8,291845 980.8%  
Depreciation Rs m3,851585 658.0%   
Interest Rs m6151,006 61.1%   
Profit before tax Rs m5,887-664 -887.3%   
Minority Interest Rs m2130-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56999 1,591.3%   
Profit after tax Rs m4,531-760 -596.2%  
Gross profit margin %20.114.3 141.0%  
Effective tax rate %26.7-14.9 -179.3%   
Net profit margin %11.0-12.8 -85.7%  
BALANCE SHEET DATA
Current assets Rs m41,4865,603 740.4%   
Current liabilities Rs m21,4136,910 309.9%   
Net working cap to sales %48.7-22.0 -220.8%  
Current ratio x1.90.8 238.9%  
Inventory Days Days64206 31.1%  
Debtors Days Days9484 112.5%  
Net fixed assets Rs m50,6619,941 509.6%   
Share capital Rs m3,00061 4,894.0%   
"Free" reserves Rs m48,8083,026 1,613.2%   
Net worth Rs m51,8083,087 1,678.3%   
Long term debt Rs m17,8985,707 313.6%   
Total assets Rs m99,89716,076 621.4%  
Interest coverage x10.60.3 3,106.5%   
Debt to equity ratio x0.31.8 18.7%  
Sales to assets ratio x0.40.4 111.9%   
Return on assets %5.21.5 336.9%  
Return on equity %8.7-24.6 -35.5%  
Return on capital %9.63.9 246.0%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m12,0581,600 753.6%   
Fx outflow Rs m7,3481,131 649.4%   
Net fx Rs m4,710469 1,005.1%   
CASH FLOW
From Operations Rs m6,6211,180 561.0%  
From Investments Rs m-6,840553 -1,237.1%  
From Financial Activity Rs m-2,397-1,644 145.8%  
Net Cashflow Rs m-2,61290 -2,911.9%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.6 1,400.0%  
FIIs % 10.7 1.3 823.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.6 84.3%  
Shareholders   109,995 10,259 1,072.2%  
Pledged promoter(s) holding % 0.0 35.1 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 13, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS